Therefore, it is necessary to conduct further animal studies to investigate the effect of EA on the upstream regulators of autophagy and necroptosis (such as NF‐kB, mTOR, AMPK, etc.)and subsequently conduct clinical trials to validate the desired effects of EA on NAFLD. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.